“anti-TNF drugs”的搜索结果，显示 791-800 项，共有 6887 项

1. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Other drugs used in the chemotherapy regimen ... treatment, in order to classify patients into post-consolidation treatment groups. ... Anti-PD-1/L1 in Patients ...

3. 血液科- 临床试验- 妙佑医疗国际

   Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by ...

4. 内分泌科- 临床试验- 妙佑医疗国际

   Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. Lutetium Lu 177 ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Usual treatment after a complete response may include observation or high dose chemotherapy followed by an autologous stem cell transplant, however, it is not ...

6. 放射科- 临床试验- 妙佑医疗国际

   The goal of this clinical trial is to learn about the safety of drug [Ac225]RTX-2358 and the diagnostic imaging agent [Cu64]LNTH-1363S. Additionally Ratio ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients ...

8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition.

9. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

10. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...